A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma

被引:42
作者
Piro, Geny [1 ,2 ,3 ]
Simionato, Francesca [3 ,4 ]
Carbone, Carmine [1 ,3 ]
Frizziero, Melissa [3 ,4 ]
Malleo, Giuseppe [3 ,5 ]
Zanini, Silvia [3 ,4 ]
Casolino, Raffaella [3 ,4 ]
Santoro, Raffaela [1 ,3 ]
Mina, Maria Mihaela [2 ,3 ]
Zecchetto, Camilla [3 ,4 ]
Merz, Valeria [3 ,4 ]
Scarpa, Aldo [3 ,6 ,7 ]
Bassi, Claudio [3 ,5 ]
Tortora, Giampaolo [2 ,3 ,4 ]
Melisi, Davide [1 ,3 ,4 ]
机构
[1] Univ Verona, Dept Med, Digest Mol Clin Oncol Res Unit, Verona, Italy
[2] Univ Verona, Dept Med, Lab Oncol & Mol Therapy, Verona, Italy
[3] Azienda Osped Univ Integrata, Comprehens Canc Ctr, Verona, Italy
[4] Azienda Osped Univ Integrata, Unit Oncol, Verona, Italy
[5] Azienda Osped Univ Integrata, Unit Gen & Pancreat Surg, Verona, Italy
[6] Univ Verona, ARC Net Res Ctr, Verona, Italy
[7] Univ Verona, Dept Pathol & Diagnost, Verona, Italy
来源
ONCOIMMUNOLOGY | 2017年 / 6卷 / 09期
关键词
circulating cytokine profile; IL4; pancreatic adenocarcinoma; prognostic biomarker; T(H)2 cytokines; REGULATORY T-CELLS; IMMUNE CONTEXTURE; CANCER; PROGRESSION; MACROPHAGE; INFLAMMATION; GEMCITABINE; RECRUITMENT; CARCINOMA;
D O I
10.1080/2162402X.2017.1322242
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Surgery is the only potentially curative option for patients with pancreatic ductal adenocarcinoma (PDAC), but metastatic relapse remains common. We hypothesized that the expression levels of inflammatory cytokines could predict recurrence of PDAC, thus allowing to select patients who most likely could benefit from surgical resection.We prospectively collected plasma at diagnosis from 287 patients with pancreatic resectable neoplasms. The expression levels of 23 cytokines were measured in 90 patients with PDAC by using a multiplex analyte profiling assay. Levels higher than cutoff identified of the T(H)2 cytokines interleukin (IL)4, IL5, IL6 of macrophage inflammatory protein (MIP)1, granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractant protein (MCP)1, and of IL17, IFN-induced protein (IP)10, and IL1b were significantly associated with a shorter median OS. In particular, levels of IL4 and IP10 higher than cutoff identified, and level of T(H)1 cytokines TNF and INF, and of IL9 and IL1R lower than cutoff identified were significantly associated with a shorter DFS. In the multivariate analysis, high IP10 was confirmed as negatively associated with OS (HR = 3.097, p = 0.014) and IL4 and TNF remain negatively (HR = 2.75, p = 0.002) and positively (HR = 0.224, p = 0.049) associated with DFS, respectively. Simultaneous expression of low IL4 and high TNF identified patients with best prognosis (HR = 0.313, p < 0.0001). In conclusion, we demonstrated that, among a series of cytokines, IL4 is the most significant independent prognostic factor for DFS in resectable PDAC patients, and it could be useful to select patients with high risk of early recurrence who may avoid an unnecessary resection.
引用
收藏
页数:7
相关论文
共 30 条
  • [21] Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies
    Sideras, K.
    Braat, H.
    Kwekkeboom, J.
    van Eijck, C. H.
    Peppelenbosch, M. P.
    Sleijfer, S.
    Bruno, M.
    [J]. CANCER TREATMENT REVIEWS, 2014, 40 (04) : 513 - 522
  • [22] Cancer Statistics, 2015
    Siegel, Rebecca L.
    Miller, Kimberly D.
    Jemal, Ahmedin
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2015, 65 (01) : 5 - 29
  • [23] TNM Seventh Edition: What's New, What's Changed Communication From the International Union Against Cancer and the American Joint Committee on Cancer
    Sobin, Leslie H.
    Compton, Carolyn C.
    [J]. CANCER, 2010, 116 (22) : 5336 - 5339
  • [24] INTERLEUKIN-4 POTENTLY ENHANCES MURINE MACROPHAGE MANNOSE RECEPTOR ACTIVITY - A MARKER OF ALTERNATIVE IMMUNOLOGICAL MACROPHAGE ACTIVATION
    STEIN, M
    KESHAV, S
    HARRIS, N
    GORDON, S
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (01) : 287 - 292
  • [25] The Desmoplastic Stroma Plays an Essential Role in the Accumulation and Modulation of Infiltrated Immune Cells in Pancreatic Adenocarcinoma
    Tjomsland, Vegard
    Niklasson, Lina
    Sandstrom, Per
    Borch, Kurt
    Druid, Henrik
    Bratthall, Charlotte
    Messmer, Davorka
    Larsson, Marie
    Spangeus, Anna
    [J]. CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2011,
  • [26] The immune network in pancreatic cancer development and progression
    Woermann, S. M.
    Diakopoulos, K. N.
    Lesina, M.
    Alguel, H.
    [J]. ONCOGENE, 2014, 33 (23) : 2956 - 2967
  • [27] Type 2 cytokines: mechanisms and therapeutic strategies
    Wynn, Thomas A.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2015, 15 (05) : 271 - 282
  • [28] Circulating CD4+CD25+ Regulatory T Cells in Patients With Pancreatic Cancer
    Yamamoto, Tomohisa
    Yanagimoto, Hiroaki
    Satoi, Sohei
    Toyokawa, Hideyoshi
    Hirooka, Satoshi
    Yamaki, So
    Yui, Rintaro
    Yamao, Jun
    Kim, Songtae
    Kwon, A-Hon
    [J]. PANCREAS, 2012, 41 (03) : 409 - 415
  • [29] YOUDEN WJ, 1950, BIOMETRICS, V6, P172, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO
  • [30] 2-3